27 completed, 9 recruiting, 7 unknown, 5 not yet recruiting. 60 Phase 1, 36 Phase 2.
Follow Hearing Loss: new trials by email Literature Review of Hearing Loss trials Research Report on Hearing Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant Otic neural progenitors, cochlear implantation - Sensorineural Hearing Loss, Presbyacusis | Phase 1 / Phase 2 | Not yet recruiting | Rinri Therapeutics | 20 | 2027-09-01 | 2026-10-01 |
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations CIL001 (Paliroden), Placebo - Cochlear Synaptopathy | Phase 1 / Phase 2 | Not yet recruiting | Cilcare SAS | 135 | 2027-01-01 | 2026-10-26 |
| A Study Testing Safety and Efficacy of Transtympanic Paliroden for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant Tinnitus paliroden (CIL001), Placebo - Tinnitus, Bilateral, Cochlear Synaptopathy | Phase 1 / Phase 2 | Not yet recruiting | Cilcare SAS | 60 | 2027-01-01 | 2026-09-17 |
| Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss Dexamethasone, Hyaluronic acid, Indocyanine green(ICG) - Hearing Loss, Sensorineural, Hearing Loss, Sudden | Phase 1 / Phase 2 | Withdrawn | Seoul National University Hospital | 2026-12-15 | 2026-05-22 | |
| Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss SKY-GJB2 - GJB2-mediated Hearing Loss, GJB2 Gene Mutation | Phase 1 / Phase 2 | Recruiting | Skylark Bio Inc. | 10 | 2026-05-28 | 2026-08-27 |
| Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) Pedmark® STS - Solid Tumor Malignancies, Testicular Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 25 | 2026-05-18 | 2026-06-18 |
| Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at low doses, Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at moderate doses, Tympanic injection of hUC-MSC-sEV-003 (small extracellular vesicles) at high doses - Sudden Hearing Loss, Extracellular Vesicles | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 9 | 2026-02-28 | 2026-03-25 |
| Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors Audiometric Test, Cisplatin, Computed Tomography - Hearing Loss, Metastatic Malignant Germ Cell Tumor | Phase 1 | Recruiting | City of Hope Medical Center | 44 | 2026-02-19 | 2026-04-17 |
| A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound - Central Auditory Processing Disorder, Hearing Impaired (Partially) | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 344 | 2025-03-31 | 2026-04-30 |
| A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) OpCT-001 - Primary Photoreceptor Disease, Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Recruiting | BlueRock Therapeutics | 54 | 2025-03-10 | 2026-10-15 |
| Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 27 | 2025-01-17 | 2026-11-04 |
| Intracochlear Application of VSF1.01 for the Reduction of Cochlear Implant Surgery Related Trauma Intracochlear application of VSF1.01 - Hearing Loss | Phase 1 / Phase 2 | Active not recruiting | Hannover Medical School | 10 | 2024-11-18 | 2026-07-16 |
| BF844 Safety and Pharmacokinetic Study in Healthy Volunteers BF844 - Usher Syndrome Type 3 | Phase 1 | Unknown | EyeXCel Pty. Ltd. | 76 | 2024-09-09 | 2024-09-19 |
| Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa AAVB-081 - Usher Syndrome, Type 1B | Phase 1 / Phase 2 | Recruiting | AAVantgarde Bio Srl | 15 | 2024-07-02 | 2025-05-02 |
| A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations SENS-501 administration - OTOF Gene Mutation, DFNB9 | Phase 1 / Phase 2 | Active not recruiting | Sensorion | 12 | 2024-06-21 | 2026-07-08 |
| A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients NS101, Placebo - Seneorineural Deafness, Sudden Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Neuracle Science Co., LTD. | 113 | 2024-02-15 | 2026-11-02 |
| Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels N-Acetylcysteine - Mitochondrial Disease | Phase 1 | Recruiting | Michio Hirano, MD | 18 | 2023-07-06 | 2026-01-23 |
| A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations DB-OTO - Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 36 | 2023-06-27 | 2026-08-05 |
| First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss FX-345, Placebo - Hearing Loss, Sensorineural | Phase 1 | Terminated | Frequency Therapeutics | 6 | 2022-12-15 | 2023-04-27 |
Showing 20 of 60. Sign in to see all of them.
Hearing Loss, Sensorineural (23) · Hearing Loss, Sudden (9) · Deafness (8) · Hearing Loss, Hidden (6) · Hearing Loss, Noise-Induced (6) · Usher Syndromes (6) · Hearing Disorders (4) · Hearing Loss, Bilateral (4) · Meniere Disease (4) · Retinitis Pigmentosa (4) · Tinnitus (4) · Diabetes Mellitus (3) · Ear Diseases (3) · Presbycusis (3)
Nervous System Diseases (60) · Neurologic Manifestations (60) · Pathological Conditions, Signs and Symptoms (60) · Sensation Disorders (60) · Signs and Symptoms (60) · Otorhinolaryngologic Diseases (59) · Ear Diseases (57) · Hearing Disorders (56) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Hearing Loss, Sensorineural (8) · Abnormalities, Multiple (7) · Blindness (7) · Congenital Abnormalities (7)
Acetylcysteine (4) · Hyaluronic Acid (3) · Cell- and Tissue-Based Therapy (2) · Cochlear Implantation (2) · Dexamethasone (2) · Hearing Aids (2) · Interleukin 1 Receptor Antagonist Protein (2) · Ringer's Lactate (2) · Saline Solution (2) · ebselen (2) · sodium thiosulfate (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Ancrod (1) · Auditory Brain Stem Implants (1) · Ciprofloxacin (1)
Frequency Therapeutics (4) · Washington University School of Medicine (4) · Andrea Vambutas (2) · Cilcare SAS (2) · James Baumgartner, MD (2) · Otonomy, Inc. (2) · Seoul National University Hospital (2) · Sound Pharmaceuticals, Incorporated (2) · AAVantgarde Bio Srl (1) · Aryn Knight (1) · Biogen (1) · BlueRock Therapeutics (1) · Children's Hospital Los Angeles (1) · Christoph Arnoldner (1) · City of Hope Medical Center (1)
United States (40) · Australia (4) · Canada (3) · France (3) · Germany (3) · United Kingdom (3) · China (2) · South Korea (2) · Austria (1) · Czechia (1) · Italy (1) · Japan (1) · Norway (1) · Spain (1) · Thailand (1)
Carl LeBel, PhD (4) · Andrea Vambutas, MD (2) · James Baumgartner, MD (2) · Aaron Tward, MD (1) · Achim Klug, PhD (1) · Alejandro Recio-Boiles, MD (1) · Alex Chehrazi-Raffle (1) · Anne Chiaramello, Ph.D. (1) · Benedict Tan, MBBS, FRACP (1) · Chris A Cardinal, PhD (1) · Debra Regier, M.D., Ph.D. (1) · Dong Pin, Doctor (1) · Douglas Hartley (1) · Egil W Martinsen, Prof. dr. med. (1)
PMID 25133431, PMID 32483557, PMID 20116419, PMID 24705452, PMID 25690605, PMID 25997115, PMID 26366332, PMID 27898605, PMID 29714549, PMID 29718280, PMID 31215818, PMID 34185708, PMID 34301203, PMID 34591079, PMID 35607935, PMID 37418643, PMID 41085057, PMID 42479273
2017 (1), 2018 (1), 2023 (1), 2025 (1), P30CA033572 (1), R01DC010075 (1), R21DK113487 (1), R33DC011827 (1), R44DC008499 (1), UH3TR003897 (1)